Durvalumab as Consolidation Therapy in Patients With LS-SCLC Following sCRT
Durvalumab as Consolidation Therapy in Patients With LS-SCLC Following sCRT
Recruiting · NCT07309211 · Registry updated 2025-12-30Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Durvalumab as Consolidation Therapy in Patients With LS-SCLC Following sCRT | SCLC, Limited Stage | Recruiting | Not stated | 2025-12-30 | NCT07309211 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| The First Affiliated Hospital with Nanjing Medical University | 319 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Cancer Hospital of Shandong First Medical University | Jinan | China | 12 |
| Nanjing Chest Hospital | Nanjing | China | 2 |
| The Affiliated Hospital of Qingdao University | Qingdao | China | 22 |
| The First Affiliated Hospital with Nanjing Medical University | Nanjing | China | 4 |